Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL6112781 | 1.00 | CA2 (0.50) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL28048398 | 1.00 | CA2 (0.50) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL28318521 | 1.00 | CA2 (0.50) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL6112776 | 1.00 | CA2 (0.50) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL345048 | 1.00 | CA2 (0.50) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL9449859 | 1.00 | CA2 (0.50) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL7565065 | 0.95 | CA2 (0.46) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL7775151 | 0.95 | CA2 (0.46) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL718179 | 0.95 | CA2 (0.46) | CA2CA1CA9BLMTDP1 | |
| Phosphoric Acid SCHEMBL4107570 | 0.95 | CA2 (0.46) | CA2CA1CA9BLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101099725-A | Method for preparing composite substrate multifunctional arterial embolic agent | DALIAN CHEMICAL PHYSICS INST (CN) | 2008-01-09 | — | — | CN | claimed |
| US-12290091-B2 | Composite materials comprising amyloid fibrils and nanoparticulate nutritional minerals | ETH ZURICH (CH) | 2025-05-06 | — | — | US | disclosed |
| EP-3585805-B1 | COMPOSITE MATERIALS COMPRISING AMYLOID FIBRILS AND NANOPARTICULATE NUTRITIONAL MINERALS | ETH ZUERICH (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-11787225-B2 | Erasing tool | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| WO-2023060067-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | MARINUS PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20220287348-A1 | COMPOSITE MATERIALS COMPRISING AMYLOID FIBRILS AND NANOPARTICULATE NUTRITIONAL MINERALS | ETH ZURICH (CH) | 2022-09-15 | — | — | US | disclosed |
| US-11344599-B2 | Composite materials comprising amyloid fibrils and nanoparticulate nutritional minerals | ETH ZURICH (CH) | 2022-05-31 | — | — | US | disclosed |
| EP-3822283-A1 | SEMAPHORIN 3A NEURODEGENERATION MODULATORS, COMPOSITIONS AND USES THEREOF | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-05-19 | — | — | EP | disclosed |
| US-20200101787-A1 | ERASING TOOL | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2020-04-02 | — | — | US | disclosed |
| EP-3611031-A1 | ERASING TOOL | Mitsubishi Pencil Company, Limited (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-20060205933-A1 | paraoxonases for treating atherosclerosis; Alzheimer's disease, neurofibromatosis, Huntington's disease, depression, amyotrophic lateral sclerosis, multiple sclerosis, stroke, Parkinson's disease, or multi-infarct dementia; biodrugs | US ARMY, SECRETARY OF THE ARMY | 2006-09-14 | — | — | US | disclosed |
| US-20050260187-A1 | Therapeutic and cosmetic uses of heparanases | INSIGHT STRATEGY & MARKETING LTD. | 2005-11-24 | — | — | US | disclosed |
| CN-1437450-A | food additive slurry composition and powder composition and food composition containing the same | MARUO CALCIUM (JP) | 2003-08-20 | — | — | CN | disclosed |
| US-20020099059-A1 | Combination therapy for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-25 | — | — | US | disclosed |
| WO-2002015899-A1 | COMBINATION THERAPY FOR THE TREATMENT OF MIGRAINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| US-5614370-A | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1995025957-A1 | HUMAN C5a ANTAGONISTS AND AGONISTS | MERCK & CO., INC. (US) | 1995-09-28 | — | — | WO | disclosed |
| EP-0539591-A1 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992001683-A1 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-06 | — | — | WO | disclosed |
| EP-0311072-A2 | Stabilization of metal ions and dispersion of particulates in aqueous systems | THE B.F. GOODRICH COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |